PPAR Inhibitors

Peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated nuclear receptors comprising three main isoforms: PPARα, PPARβ/δ, and PPARγ. These receptors play crucial roles in regulating gene expression involved in lipid and glucose metabolism, inflammation, cell differentiation, and proliferation. Upon binding to their specific lipid-derived ligands, PPARs heterodimerize with retinoid X receptors (RXRs) and bind to specific DNA sequences known as PPAR response elements (PPREs) in the promoter regions of target genes, thereby modulating their transcription. Each PPAR isoform exhibits distinct tissue distribution and physiological functions. PPARα is predominantly expressed in tissues with high fatty acid catabolism, such as the liver, heart, and muscle, and primarily regulates fatty acid oxidation. PPARγ is highly expressed in adipose tissue, where it is critical for adipogenesis, lipid storage, and insulin sensitization, and also found in immune cells. PPARβ/δ is ubiquitously expressed and involved in fatty acid oxidation, cell proliferation, and differentiation in various tissues. While PPAR *agonists* are well-established therapeutic agents—fibrates (PPARα agonists) for dyslipidemia and glitazones (PPARγ agonists) for type 2 diabetes—PPAR *inhibitors* represent a more nascent but increasingly explored area of research.

The rationale for PPAR inhibition stems from contexts where their activity is detrimental. For instance, in certain cancers, PPARγ can promote cell proliferation, survival, and differentiation, making its inhibition a potential anti-cancer strategy. This is particularly relevant in cancers where PPARγ is overexpressed or aberrantly activated, such as colon, breast, prostate, and lung cancers, as well as liposarcomas. Inhibiting PPARγ in these settings could suppress tumor growth and induce apoptosis. Furthermore, in conditions where excessive adipogenesis or lipid accumulation contributes to disease pathology, such as obesity-related complications or certain metabolic dysfunctions, PPARγ inhibition might be considered. Research progress on direct PPAR inhibitors is primarily in the preclinical stage. Specific PPARγ antagonists, such as GW9662 and T0070907, are widely used as research tools to elucidate the precise roles of PPARγ in various cellular processes and disease models. These compounds act as competitive antagonists or inverse agonists, blocking ligand binding or actively repressing PPARγ transcriptional activity.

Preclinical studies have demonstrated their anti-proliferative and pro-apoptotic effects in various cancer cell lines and xenograft models. Efforts are also underway to develop more selective and potent inhibitors for specific PPAR isoforms, as well as pan-PPAR inhibitors, although the latter approach carries a higher risk of broad metabolic side effects. Classifications of PPAR inhibitors are typically based on their selectivity for specific isoforms (e.g., selective PPARγ antagonists) and their mechanism of action (e.g., competitive antagonists, inverse agonists). The chemical structures of these inhibitors are diverse, ranging from small molecules to more complex scaffolds. A significant challenge in developing PPAR inhibitors is the complex and often context-dependent roles of PPARs; for example, PPARγ can exhibit both tumor-suppressive and tumor-promoting functions depending on the cancer type and genetic background. This necessitates careful patient stratification and biomarker identification. Potential metabolic side effects, given PPARs' central role in metabolism, also require careful consideration. Combination therapies, where PPAR inhibitors are used to enhance the efficacy of conventional chemotherapy or other targeted agents, are being explored to overcome resistance and improve therapeutic outcomes in cancer.